Article
Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines.
Therapeutic drug monitoring - 1 Oct 2013
Elens Laure, Capron Arnaud, van Schaik Ron H N, De Meyer Martine, De Pauw Luc, Eddour Djamila C, Latinne Dominique, Wallemacq Pierre, Mourad Michel, Haufroid Vincent
Abstract excerpt
BACKGROUND: Tacrolimus (Tac) metabolism is mainly mediated by the cytochrome P450 3A (CYP3A) subfamily. Recently, it has been reported that kidney transplant recipients carrying the CYP3A4*22 decrease-of-function allele require lower Tac doses and are more at risk of Tac overexposure than CYP3A4*1/*1 patients. This effect was shown to be independent of the CYP3A5*3 allelic status. However, the pharmacokinetic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.